Unity outlines path forward for anti-aging programs after Phase II osteoarthritis failure

After the failure of its lead anti-aging program in osteoarthritis, Unity believes more objective clinical endpoints and robust preclinical data for its next-in-line ophthalmology candidate mean that program won’t suffer the same fate in the clinic.

Shares of Unity Biotechnology Inc. (NASDAQ:UBX) fell $8.28 (67%) to $4.15 on Monday after the San Francisco company reported that UBX0101 failed to meet the 12-week primary endpoint of change from baseline in WOMAC-A vs. placebo in a Phase II study of patients with moderate to severe painful osteoarthritis of the knee. It does not plan to advance UBX0101 into pivotal studies. ...